EVALUATION OF MEDICINES FROM WHO MODEL LIST OF ESSENTIAL MEDICINES WITHIN NATIONAL HTA PROCEDURE IN UKRAINE: FINDINGS AND IMPLICATIONS
Author(s)
Oresta Piniazhko, PhD1, Elizaveta Otrubchak, MSc1, Valeriia Serediuk, MSc1, Iryna Musiienko, MSc1, Iuliia Malyshevska, MSc1, Yevheniia Ishkova, PhD1, Yevhenii Honchar, MSc2, Lorenzo Moja, PhD3.
1State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine, 2Ministry of Health of Ukraine, Kyiv, Ukraine, 3World health organization (WHO), Geneva, Switzerland.
1State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine, 2Ministry of Health of Ukraine, Kyiv, Ukraine, 3World health organization (WHO), Geneva, Switzerland.
OBJECTIVES: The WHO Model List of Essential Medicines (EML) includes medicines that address priority healthcare needs and supports evidence-informed healthcare policy. However, inclusion in the EML does not necessarily imply cost-effectiveness across different healthcare systems. This study aimed to assess whether medicines included in the WHO EML for the same indication were considered cost-effective within the Ukrainian healthcare system based on national HTA conclusions.
METHODS:
A review of Ukrainian HTA conclusions published between 2021 and 2026 was conducted. Among 96 completed HTA conclusions, medicines included in the WHO EML for the corresponding indication were identified and analyzed. Cost-effectiveness outcomes were categorized as efficient spending, low-efficient spending, or inefficient spending according to the conclusions reported in the HTA assessments.
RESULTS: Of the 96 HTA conclusions identified, 23 (24.0%) assessed medicines were included in the WHO EML for the same indication. Among these assessments, 11 (47.8%) concluded that the medicines represented efficient spending, 2 (8.7%) low-efficient spending, and 10 (43.5%) inefficient spending within the Ukrainian healthcare setting. Certain recommendations accompanying the listing of essential medicines - relating to the use of those essential medicines themselves or to price control policies - may influence the determination of the economic value of these medicines.
CONCLUSIONS: Findings demonstrate considerable variability in the economic value of EML-listed medicines when assessed within Ukrainian HTA framework. While nearly half of the evaluated technologies were considered efficient spending in Ukraine, more than 40% were classified as inefficient spending based on national HTA assessments. In several cases, access to these medicines required price negotiations via managed entry agreements, or other reimbursement mechanisms to improve their economic value.
METHODS:
A review of Ukrainian HTA conclusions published between 2021 and 2026 was conducted. Among 96 completed HTA conclusions, medicines included in the WHO EML for the corresponding indication were identified and analyzed. Cost-effectiveness outcomes were categorized as efficient spending, low-efficient spending, or inefficient spending according to the conclusions reported in the HTA assessments.
RESULTS: Of the 96 HTA conclusions identified, 23 (24.0%) assessed medicines were included in the WHO EML for the same indication. Among these assessments, 11 (47.8%) concluded that the medicines represented efficient spending, 2 (8.7%) low-efficient spending, and 10 (43.5%) inefficient spending within the Ukrainian healthcare setting. Certain recommendations accompanying the listing of essential medicines - relating to the use of those essential medicines themselves or to price control policies - may influence the determination of the economic value of these medicines.
CONCLUSIONS: Findings demonstrate considerable variability in the economic value of EML-listed medicines when assessed within Ukrainian HTA framework. While nearly half of the evaluated technologies were considered efficient spending in Ukraine, more than 40% were classified as inefficient spending based on national HTA assessments. In several cases, access to these medicines required price negotiations via managed entry agreements, or other reimbursement mechanisms to improve their economic value.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
HTA215
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas